nodes	percent_of_prediction	percent_of_DWPC	metapath
Meprobamate—CYP2E1—Mitoxantrone—lymphatic system cancer	0.193	0.338	CbGbCtD
Meprobamate—CYP2C19—Teniposide—lymphatic system cancer	0.173	0.303	CbGbCtD
Meprobamate—ABCB1—Mitoxantrone—lymphatic system cancer	0.0978	0.171	CbGbCtD
Meprobamate—ABCB1—Vincristine—lymphatic system cancer	0.0673	0.118	CbGbCtD
Meprobamate—ABCB1—Methotrexate—lymphatic system cancer	0.0408	0.0712	CbGbCtD
Meprobamate—Hypotensive—Teniposide—lymphatic system cancer	0.0278	0.0652	CcSEcCtD
Meprobamate—Petechiae—Mechlorethamine—lymphatic system cancer	0.0167	0.0392	CcSEcCtD
Meprobamate—Oliguria—Mechlorethamine—lymphatic system cancer	0.015	0.035	CcSEcCtD
Meprobamate—Dermatitis bullous—Mechlorethamine—lymphatic system cancer	0.0105	0.0245	CcSEcCtD
Meprobamate—Anuria—Methotrexate—lymphatic system cancer	0.00757	0.0177	CcSEcCtD
Meprobamate—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00719	0.0168	CcSEcCtD
Meprobamate—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00654	0.0153	CcSEcCtD
Meprobamate—Petechiae—Mitoxantrone—lymphatic system cancer	0.00646	0.0151	CcSEcCtD
Meprobamate—Bronchospasm—Teniposide—lymphatic system cancer	0.00627	0.0147	CcSEcCtD
Meprobamate—Stomatitis—Teniposide—lymphatic system cancer	0.00554	0.013	CcSEcCtD
Meprobamate—Vertigo—Mechlorethamine—lymphatic system cancer	0.00541	0.0127	CcSEcCtD
Meprobamate—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00539	0.0126	CcSEcCtD
Meprobamate—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00495	0.0116	CcSEcCtD
Meprobamate—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00492	0.0115	CcSEcCtD
Meprobamate—Stomatitis—Fludarabine—lymphatic system cancer	0.00487	0.0114	CcSEcCtD
Meprobamate—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.0048	0.0112	CcSEcCtD
Meprobamate—Chills—Teniposide—lymphatic system cancer	0.00458	0.0107	CcSEcCtD
Meprobamate—Arrhythmia—Teniposide—lymphatic system cancer	0.00456	0.0107	CcSEcCtD
Meprobamate—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00424	0.00992	CcSEcCtD
Meprobamate—Agitation—Teniposide—lymphatic system cancer	0.00408	0.00955	CcSEcCtD
Meprobamate—Bronchospasm—Bleomycin—lymphatic system cancer	0.00404	0.00945	CcSEcCtD
Meprobamate—Chills—Fludarabine—lymphatic system cancer	0.00402	0.00941	CcSEcCtD
Meprobamate—Arrhythmia—Fludarabine—lymphatic system cancer	0.004	0.00937	CcSEcCtD
Meprobamate—Leukopenia—Teniposide—lymphatic system cancer	0.00397	0.0093	CcSEcCtD
Meprobamate—Ataxia—Carmustine—lymphatic system cancer	0.0039	0.00913	CcSEcCtD
Meprobamate—Ataxia—Vincristine—lymphatic system cancer	0.00372	0.00871	CcSEcCtD
Meprobamate—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00362	0.00848	CcSEcCtD
Meprobamate—Agitation—Fludarabine—lymphatic system cancer	0.00359	0.00839	CcSEcCtD
Meprobamate—Stomatitis—Bleomycin—lymphatic system cancer	0.00357	0.00835	CcSEcCtD
Meprobamate—Tachycardia—Teniposide—lymphatic system cancer	0.00354	0.00828	CcSEcCtD
Meprobamate—Leukopenia—Fludarabine—lymphatic system cancer	0.00349	0.00818	CcSEcCtD
Meprobamate—Pruritus—Mechlorethamine—lymphatic system cancer	0.00348	0.00814	CcSEcCtD
Meprobamate—Hypotension—Teniposide—lymphatic system cancer	0.00339	0.00792	CcSEcCtD
Meprobamate—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00336	0.00787	CcSEcCtD
Meprobamate—Petechiae—Methotrexate—lymphatic system cancer	0.00322	0.00753	CcSEcCtD
Meprobamate—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00318	0.00745	CcSEcCtD
Meprobamate—Vomiting—Mechlorethamine—lymphatic system cancer	0.00313	0.00731	CcSEcCtD
Meprobamate—Stomatitis—Carmustine—lymphatic system cancer	0.00312	0.00729	CcSEcCtD
Meprobamate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0031	0.00725	CcSEcCtD
Meprobamate—Stomatitis—Vincristine—lymphatic system cancer	0.00297	0.00696	CcSEcCtD
Meprobamate—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00297	0.00695	CcSEcCtD
Meprobamate—Chills—Bleomycin—lymphatic system cancer	0.00295	0.0069	CcSEcCtD
Meprobamate—Nausea—Mechlorethamine—lymphatic system cancer	0.00292	0.00683	CcSEcCtD
Meprobamate—Stomatitis—Mitoxantrone—lymphatic system cancer	0.0029	0.00678	CcSEcCtD
Meprobamate—Oliguria—Methotrexate—lymphatic system cancer	0.00287	0.00672	CcSEcCtD
Meprobamate—Body temperature increased—Teniposide—lymphatic system cancer	0.00286	0.0067	CcSEcCtD
Meprobamate—Paraesthesia—Fludarabine—lymphatic system cancer	0.00286	0.00669	CcSEcCtD
Meprobamate—Oedema peripheral—Carmustine—lymphatic system cancer	0.00283	0.00661	CcSEcCtD
Meprobamate—Dysarthria—Methotrexate—lymphatic system cancer	0.0028	0.00655	CcSEcCtD
Meprobamate—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00277	0.00649	CcSEcCtD
Meprobamate—Hypersensitivity—Teniposide—lymphatic system cancer	0.00267	0.00625	CcSEcCtD
Meprobamate—Asthenia—Teniposide—lymphatic system cancer	0.0026	0.00608	CcSEcCtD
Meprobamate—Pruritus—Teniposide—lymphatic system cancer	0.00256	0.006	CcSEcCtD
Meprobamate—Arrhythmia—Carmustine—lymphatic system cancer	0.00256	0.006	CcSEcCtD
Meprobamate—Leukopenia—Bleomycin—lymphatic system cancer	0.00256	0.00599	CcSEcCtD
Meprobamate—Body temperature increased—Fludarabine—lymphatic system cancer	0.00252	0.00589	CcSEcCtD
Meprobamate—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00248	0.00581	CcSEcCtD
Meprobamate—Diarrhoea—Teniposide—lymphatic system cancer	0.00248	0.0058	CcSEcCtD
Meprobamate—Chills—Mitoxantrone—lymphatic system cancer	0.00239	0.0056	CcSEcCtD
Meprobamate—Ecchymosis—Methotrexate—lymphatic system cancer	0.00239	0.0056	CcSEcCtD
Meprobamate—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00238	0.00558	CcSEcCtD
Meprobamate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00235	0.00549	CcSEcCtD
Meprobamate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00234	0.00547	CcSEcCtD
Meprobamate—Vomiting—Teniposide—lymphatic system cancer	0.0023	0.00539	CcSEcCtD
Meprobamate—Agitation—Carmustine—lymphatic system cancer	0.0023	0.00537	CcSEcCtD
Meprobamate—Asthenia—Fludarabine—lymphatic system cancer	0.00229	0.00535	CcSEcCtD
Meprobamate—Dermatitis—Teniposide—lymphatic system cancer	0.00228	0.00534	CcSEcCtD
Meprobamate—Headache—Teniposide—lymphatic system cancer	0.00227	0.00531	CcSEcCtD
Meprobamate—Pruritus—Fludarabine—lymphatic system cancer	0.00225	0.00527	CcSEcCtD
Meprobamate—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00225	0.00527	CcSEcCtD
Meprobamate—Leukopenia—Carmustine—lymphatic system cancer	0.00224	0.00523	CcSEcCtD
Meprobamate—Agitation—Vincristine—lymphatic system cancer	0.00219	0.00513	CcSEcCtD
Meprobamate—Hypotension—Bleomycin—lymphatic system cancer	0.00218	0.00511	CcSEcCtD
Meprobamate—Diarrhoea—Fludarabine—lymphatic system cancer	0.00218	0.0051	CcSEcCtD
Meprobamate—Nausea—Teniposide—lymphatic system cancer	0.00215	0.00504	CcSEcCtD
Meprobamate—Vertigo—Vincristine—lymphatic system cancer	0.00214	0.00501	CcSEcCtD
Meprobamate—Leukopenia—Vincristine—lymphatic system cancer	0.00213	0.00499	CcSEcCtD
Meprobamate—Paraesthesia—Bleomycin—lymphatic system cancer	0.0021	0.00491	CcSEcCtD
Meprobamate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00208	0.00486	CcSEcCtD
Meprobamate—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00204	0.00476	CcSEcCtD
Meprobamate—Vomiting—Fludarabine—lymphatic system cancer	0.00203	0.00474	CcSEcCtD
Meprobamate—Dermatitis—Fludarabine—lymphatic system cancer	0.00201	0.0047	CcSEcCtD
Meprobamate—Headache—Fludarabine—lymphatic system cancer	0.002	0.00467	CcSEcCtD
Meprobamate—Tachycardia—Carmustine—lymphatic system cancer	0.00199	0.00466	CcSEcCtD
Meprobamate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00195	0.00455	CcSEcCtD
Meprobamate—Hypotension—Carmustine—lymphatic system cancer	0.0019	0.00446	CcSEcCtD
Meprobamate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00189	0.00443	CcSEcCtD
Meprobamate—Nausea—Fludarabine—lymphatic system cancer	0.00189	0.00443	CcSEcCtD
Meprobamate—Shock—Mitoxantrone—lymphatic system cancer	0.00186	0.00436	CcSEcCtD
Meprobamate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00185	0.00433	CcSEcCtD
Meprobamate—Body temperature increased—Bleomycin—lymphatic system cancer	0.00185	0.00432	CcSEcCtD
Meprobamate—Paraesthesia—Carmustine—lymphatic system cancer	0.00183	0.00428	CcSEcCtD
Meprobamate—Hypotension—Vincristine—lymphatic system cancer	0.00182	0.00426	CcSEcCtD
Meprobamate—Somnolence—Carmustine—lymphatic system cancer	0.00181	0.00424	CcSEcCtD
Meprobamate—Ataxia—Methotrexate—lymphatic system cancer	0.00181	0.00423	CcSEcCtD
Meprobamate—Hypotension—Mitoxantrone—lymphatic system cancer	0.00177	0.00414	CcSEcCtD
Meprobamate—Paraesthesia—Vincristine—lymphatic system cancer	0.00175	0.00409	CcSEcCtD
Meprobamate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00172	0.00403	CcSEcCtD
Meprobamate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0017	0.00398	CcSEcCtD
Meprobamate—Somnolence—Mitoxantrone—lymphatic system cancer	0.00168	0.00394	CcSEcCtD
Meprobamate—Asthenia—Bleomycin—lymphatic system cancer	0.00168	0.00392	CcSEcCtD
Meprobamate—Pruritus—Bleomycin—lymphatic system cancer	0.00165	0.00387	CcSEcCtD
Meprobamate—Eosinophilia—Methotrexate—lymphatic system cancer	0.00164	0.00385	CcSEcCtD
Meprobamate—Body temperature increased—Carmustine—lymphatic system cancer	0.00161	0.00377	CcSEcCtD
Meprobamate—Body temperature increased—Vincristine—lymphatic system cancer	0.00154	0.0036	CcSEcCtD
Meprobamate—Hypersensitivity—Carmustine—lymphatic system cancer	0.0015	0.00351	CcSEcCtD
Meprobamate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0015	0.00351	CcSEcCtD
Meprobamate—Vomiting—Bleomycin—lymphatic system cancer	0.00148	0.00347	CcSEcCtD
Meprobamate—Drowsiness—Methotrexate—lymphatic system cancer	0.00148	0.00346	CcSEcCtD
Meprobamate—Dermatitis—Bleomycin—lymphatic system cancer	0.00147	0.00344	CcSEcCtD
Meprobamate—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00147	0.00343	CcSEcCtD
Meprobamate—Asthenia—Carmustine—lymphatic system cancer	0.00146	0.00342	CcSEcCtD
Meprobamate—Stomatitis—Methotrexate—lymphatic system cancer	0.00144	0.00338	CcSEcCtD
Meprobamate—Hypersensitivity—Vincristine—lymphatic system cancer	0.00143	0.00336	CcSEcCtD
Meprobamate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.0014	0.00327	CcSEcCtD
Meprobamate—Asthenia—Vincristine—lymphatic system cancer	0.0014	0.00327	CcSEcCtD
Meprobamate—Diarrhoea—Carmustine—lymphatic system cancer	0.00139	0.00326	CcSEcCtD
Meprobamate—Nausea—Bleomycin—lymphatic system cancer	0.00139	0.00325	CcSEcCtD
Meprobamate—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00138	0.00323	CcSEcCtD
Meprobamate—Asthenia—Mitoxantrone—lymphatic system cancer	0.00136	0.00318	CcSEcCtD
Meprobamate—Dizziness—Carmustine—lymphatic system cancer	0.00135	0.00315	CcSEcCtD
Meprobamate—Diarrhoea—Vincristine—lymphatic system cancer	0.00133	0.00312	CcSEcCtD
Meprobamate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0013	0.00303	CcSEcCtD
Meprobamate—Vomiting—Carmustine—lymphatic system cancer	0.0013	0.00303	CcSEcCtD
Meprobamate—Dizziness—Vincristine—lymphatic system cancer	0.00129	0.00301	CcSEcCtD
Meprobamate—Dermatitis—Carmustine—lymphatic system cancer	0.00128	0.00301	CcSEcCtD
Meprobamate—Headache—Carmustine—lymphatic system cancer	0.00128	0.00299	CcSEcCtD
Meprobamate—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00126	0.00294	CcSEcCtD
Meprobamate—Vomiting—Vincristine—lymphatic system cancer	0.00124	0.0029	CcSEcCtD
Meprobamate—Dermatitis—Vincristine—lymphatic system cancer	0.00123	0.00287	CcSEcCtD
Meprobamate—Headache—Vincristine—lymphatic system cancer	0.00122	0.00285	CcSEcCtD
Meprobamate—Nausea—Carmustine—lymphatic system cancer	0.00121	0.00283	CcSEcCtD
Meprobamate—Vomiting—Mitoxantrone—lymphatic system cancer	0.0012	0.00282	CcSEcCtD
Meprobamate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00119	0.00279	CcSEcCtD
Meprobamate—Chills—Methotrexate—lymphatic system cancer	0.00119	0.00279	CcSEcCtD
Meprobamate—Headache—Mitoxantrone—lymphatic system cancer	0.00119	0.00278	CcSEcCtD
Meprobamate—Nausea—Vincristine—lymphatic system cancer	0.00116	0.0027	CcSEcCtD
Meprobamate—Nausea—Mitoxantrone—lymphatic system cancer	0.00113	0.00263	CcSEcCtD
Meprobamate—Vertigo—Methotrexate—lymphatic system cancer	0.00104	0.00243	CcSEcCtD
Meprobamate—Leukopenia—Methotrexate—lymphatic system cancer	0.00104	0.00242	CcSEcCtD
Meprobamate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000944	0.00221	CcSEcCtD
Meprobamate—Hypotension—Methotrexate—lymphatic system cancer	0.000882	0.00206	CcSEcCtD
Meprobamate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000848	0.00198	CcSEcCtD
Meprobamate—Somnolence—Methotrexate—lymphatic system cancer	0.000839	0.00196	CcSEcCtD
Meprobamate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000746	0.00175	CcSEcCtD
Meprobamate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000696	0.00163	CcSEcCtD
Meprobamate—Asthenia—Methotrexate—lymphatic system cancer	0.000677	0.00159	CcSEcCtD
Meprobamate—Pruritus—Methotrexate—lymphatic system cancer	0.000668	0.00156	CcSEcCtD
Meprobamate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000646	0.00151	CcSEcCtD
Meprobamate—Dizziness—Methotrexate—lymphatic system cancer	0.000624	0.00146	CcSEcCtD
Meprobamate—Vomiting—Methotrexate—lymphatic system cancer	0.0006	0.0014	CcSEcCtD
Meprobamate—Dermatitis—Methotrexate—lymphatic system cancer	0.000595	0.00139	CcSEcCtD
Meprobamate—Headache—Methotrexate—lymphatic system cancer	0.000591	0.00138	CcSEcCtD
Meprobamate—Nausea—Methotrexate—lymphatic system cancer	0.000561	0.00131	CcSEcCtD
